Pharmaceutical firm Indoco Remedies announced Q3FY23 results: Q3FY23 vs Q3FY22: During the Q3FY23, revenues of Indoco Remedies grew by 17.8% at Rs 410.6 crore, as against Rs 348.6 crore, in the same quarter last year. EBIDTA to net sales for the quarter is 15.0% at Rs 61.7 crore, compared to 21.1% at Rs 73.4 crore, in the same quarter last year. EBIDTA to net sales without the impact of other operating income stands at 17.9 %. For the quarter, the profit after tax is Rs 27.9 crore. 9MFY23 vs 9MFY22: The revenues grew by 9.8% at Rs 1,210.1 crore, as against Rs 1,102.4 crore, in the same period last year. EBIDTA to net sales for the period is 18.2% at Rs 220.7 crore, compared to 22.4% at Rs 246.5 crore, in the same period last year. During the period, the profit after tax is Rs 116 crore. Commenting on the third quarter FY23 results, Aditi Panandikar, Managing Director, Indoco Remedies Ltd. said, “A good performance in Domestic business and an excellent growth in Export business has allowed us to post good results this quarter”. Result PDF
Pharmaceuticals company Indoco Remedies announced Q2FY23 results: Q2FY23: During the Second quarter of FY23, revenues of Indoco Remedies grew by 8.6 % at Rs 404.6 crore, as against Rs 372.6 crore, the same quarter last year EBIDTA to net sales for the quarter is 21.7 % at Rs 87.8 crore, compared to 23.2 % at Rs 86.3 crore, the same quarter last year For the quarter, the Profit After Tax to net sales is 12.3 % at Rs 49.6 crore, compared to 11.2 % at Rs 41.6 crore, the same quarter last year H1FY23: For the first half of FY23, the revenues grew by 6.1 % at Rs 799.5 crore, as against Rs 753.8 crore, the same period last year EBIDTA to net sales for the period is 19.9 % at Rs 159.1 crore, compared to 23.0 % at Rs 173.1 crore, the same period last year For the period, the Profit After Tax to net sales is 11.0 % at Rs 88.1 crore, compared to 10.8 % at Rs 81.2 crore, the same period last year Commenting on the second quarter FY 2022-23 results, Aditi Panandikar, Managing Director, Indoco Remedies Ltd., said, “An excellent performance driven by international formulation sales and ably supported by domestic business has helped us deliver improved margins this quarter”. Result PDF